logo

English
  • Svenska
  • About Us
    About Us
      • This is Calliditas
      • Vision and Strategy
      • Board of Directors
      • Management Team
      • Our History
      • Corporate Responsibility
        • Expanded Access Policy
      • Careers
  • Science
    Science
      • Our Pipeline
      • Nefecon (ex-US Markets)
      • Setanaxib – NOX Platform
      • Orphan drugs
  • Our Product
  • Governance
    Governance
      • Corporate Governance
      • Corporate Governance Reports
      • Corporate Structure
      • General Meeting
        • Annual general meeting 2022
        • General meetings
      • Nomination Committee
        • Nomination committees
      • Board and Committees
        • Board of Directors
        • Board fees
        • Work of the Board of Directors
        • Committees
      • Management
        • Management team
      • Remuneration
      • Internal Control and Risk Management
      • Auditor
      • Articles of Association
  • Investors
    Investors
      • The Share
        • Trading information
        • Ownership structure
        • Share capital development
        • Dividend policy
        • Analyst coverage
      • Financial Reports and Presentations
      • SEC Filings
      • Press Releases
      • Financial Calendar
      • IR Calendar
      • Subscribe
      • Contacts
      • Investor FAQs
  • Media
    Media
      • Press releases
      • Calliditas in Media
      • Calliditas Media Kit
      • TARPEYO Media Kit (US audience only)
      • Subscribe
      • Contacts
  • Contact Us
    Contact Us
      • Offices
      • Partnerships and Inquires
      • Investor Relations
      • Media
      • Medical Inquiries
  • Svenska

Financial Reports and Presentations
2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
Annual Reports
  • Company presentations
  • Interim Reports
  • Presentations
  • All types
  Report Presentation Webcast
April 27, 2022 Annual report 2021
  • Investors
    • The Share
      • Trading information
      • Ownership structure
      • Share capital development
      • Dividend policy
      • Analyst coverage
    • Financial Reports and Presentations
    • SEC Filings
    • Press Releases
    • Financial Calendar
    • IR Calendar
    • Subscribe
    • Contacts
    • Investor FAQs

Calliditas Therapeutics AB
D5, Kungsbron 1
SE-111 22 Stockholm
Sweden

Company number: 556659-9766

  • Privacy policy
  • About cookies

© Calliditas Therapeutics AB 2022